In this on-demand Webcast of a live symposium in Atlanta, Georgia, expert faculty review optimal care for patients with myeloma, including diagnosis and current and emerging treatment approaches.
To view the activity in its entirety and receive CME credits,
Learning Objectives:
Topics covered
|
Faculty:
Credit Information: Release date: April 30, 2018 Physicians: maximum of 2.5 AMA PRA Category 1 Credits™ |
|
|
Disclosures of Conflict of Interest | |
The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: |
|
Faculty | |
Brian G.M. Durie, MD |
Disclosed that he has received consulting fees from Celgene, Johnson & Johnson, Onyx, and Takeda. |
Philippe Moreau, MD |
Disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda. |
Bruno Paiva, PhD |
Disclosed that he has received consulting fees from Celgene, Janssen, Merck, Novartis, and Takeda, funds for contracted research from Celgene, EngMab and sanofi, and fees for non-CME/CE services from Amgen, Celgene, Janssen, and Takeda. |
S. Vincent Rajkumar, MD |
No real or apparent conflicts of interest to report. |
Jesús F. San-Miguel, MD, PhD |
Disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, Janssen, MSD, Novartis, Takeda, sanofi-aventis, and Roche. |
Staff |
|
Kristen Rosenthal, PhD; Terrence Fagan; Gordon Kelley; and Kevin Obholz, PhD |
No real or apparent conflicts of interest to report. |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. |
|
|
|
Target Audience Goal |
Learning Objectives
|
|
|
Physician Continuing Education | |
Accreditation Statement This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the International Myeloma Foundation, and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
|
|
|
Commercial Support |
This activity is supported by educational grants from Amgen, Celgene Corporation, Janssen, Karyopharm, Takeda Oncology, and The Binding Site. |
|
|
Program Medium |
This program has been made available online. |
|
|
Site Requirements |
|
|
|
Instruction for Credit | |
Participation in this self-study activity should be completed in approximately 2.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 30, 2018, through April 29, 2019 1. Register online at http://www.clinicaloptions.com.
|